This week's Fierce Biotech is brought to you by Natera.

Virtual Event: Latest Data in Breast Cancer Response Monitoring and Relapse Prediction

Tuesday, December 14, 2021 | 1pm ET / 10am PT

Following SABCS, learn about the latest advances and clinical data in monitoring response to treatment and identifying patients at high risk of relapse in breast cancer.

Join us for a discussion of data showcasing the validity and utility of using circulating tumor DNA (ctDNA) across neoadjuvant, post-surgical / adjuvant, and metastatic settings.

Save Your Spot - Register Today

We will cover the latest clinical data from 2021 and 2020 publications and presentations (including SABCS and Nature), prospective studies leveraging ctDNA to enroll breast cancer patients, as well as discuss future implications for clinical trials and clinical practice.

You are currently subscribed as newsletter@newslettercollector.com
If you no longer wish to receive promotions from Fierce LifeSciences, simply unsubscribe.
Refer to our Privacy Policy.

Fierce LifeSciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2021 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission.